Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
MWN-AI** Summary
Monopar Therapeutics Inc. (Nasdaq: MNPR) reported its financial results for the second quarter of 2025, alongside significant recent developments, on August 12, 2025. The company, focused on innovative therapies for unmet medical needs, marked a pivotal moment with the transfer of the investigational new drug application for ALXN1840 for Wilson disease from Alexion Pharmaceuticals, acknowledged by the FDA on July 29, 2025. Monopar now leads the program and aims to submit a New Drug Application (NDA) in early 2026.
Monopar's ongoing clinical trials include both imaging and therapeutic investigations of MNPR-101-Zr and MNPR-101-Lu for advanced cancers in Australia and the U.S., where an Expanded Access Program is also in place. Additionally, preclinical work on MNPR-101-Ac is advancing towards clinical readiness.
Financially, Monopar reported cash reserves of $53.3 million as of June 30, 2025, expected to fund operations through at least December 31, 2026. The net loss for the second quarter was $2.5 million, translating to $0.35 per share, increasing from a loss of $1.7 million, or $0.49 per share, in the same quarter of 2024. Research and development expenses rose to $1.73 million, driven by staffing increases, while general and administrative expenses surged to $1.5 million due to board compensations and rising legal fees.
Notably, interest income increased significantly, reflecting the impact of funds raised in late 2024. Monopar Therapeutics continues to solidify its position in the biopharmaceutical landscape, with forward-looking statements addressing potential regulatory and funding challenges as it progresses toward regulatory approvals and new developments. For detailed information, visit their official website.
MWN-AI** Analysis
Monopar Therapeutics (NASDAQ: MNPR) reports solid second-quarter results amid significant developments in its drug pipeline, particularly with ALXN1840 for Wilson disease, now fully under its stewardship. The FDA's acknowledgment of the transfer allows Monopar to prepare for a New Drug Application (NDA) submission in early 2026, which could boost investor sentiment as the company awaits the results of their clinical trials.
The company's cash position of $53.3 million provides a runway through at least December 2026, a reassuring buffer while advancing its therapeutic programs. However, the increase in net loss to $2.5 million and rising R&D and G&A expenses necessitate close scrutiny. The net loss per share reduction from $0.49 in Q2 2024 to $0.35 signifies potential operational efficiencies, yet the hike in R&D expenses to $1.73 million raises questions about capital allocation and management efficacy, particularly as it relates to the $55 million raised in the fourth quarter of 2024.
Investors should also note the growing interest income, attributed to higher treasury security yields, hinting at effective cash management practices. This aspect may help buffer ongoing operational losses, but the broader question remains: can Monopar successfully navigate the competitive landscape post-NDA approval?
Market sentiment may remain cautious as Monopar faces challenges inherent to clinical-stage companies, including stringent regulatory scrutiny and market competition from established pharmaceutical firms. Potential strategic partnerships could enhance Monopar’s go-to-market feasibility for ALXN1840 and its radiopharmaceutical offerings.
Overall, while the groundwork is promising for future growth, investors should prepare for volatility relating to trial outcomes and regulatory developments. A conservative approach emphasizing risk management through diversified investments may be prudent, given the inherent uncertainties in biotech investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical?stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments.
Recent Developments
ALXN1840 for Wilson Disease
On June 6, 2025, Alexion Pharmaceuticals officially transferred sponsorship of the investigational new drug (“IND”) application for ALXN1840 to Monopar. The U.S. Food and Drug Administration (“FDA”) acknowledged this change on July 29, 2025, confirming that the transfer was effective as of June 6, 2025. Monopar is now fully responsible for the program, including its commercial advancement and compliance with all applicable federal regulations.
Monopar is preparing to submit a New Drug Application (“NDA”) to the FDA in early 2026.
MNPR ? 101 for Radiopharmaceutical Use
The Company’s MNPR-101-Zr Phase 1 (imaging and dosimetry) and MNPR-101-Lu (therapeutic) Phase 1a clinical trials in advanced cancers are active and enrolling in Australia, and the Company’s Expanded Access Program (also referred to as compassionate use) for MNPR-101-Zr and MNPR-101-Lu is active and enrolling in the U. S. Monopar continues its preclinical work with MNPR-101-Ac (therapeutic) with plans to enter the clinic in the future.
Financial Results for the Second Quarter Ended June 30, 2025, Compared to the Second Quarter Ended June 30, 2024
Cash and Net Loss
Cash, cash equivalents and investments as of June 30, 2025, were $53.3 million. Monopar expects that its current funds will be sufficient to continue operations at least through December 31, 2026, in order to: (1) assemble a regulatory package and file an NDA for ALXN1840; (2) continue to conduct and conclude its first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr; (3) continue to conduct its first-in-human therapeutic clinical trial of MNPR-101-Lu; (4) advance its preclinical MNPR-101-Ac program into the clinic; and (5) invest in internal research and development projects to expand its radiopharmaceutical and rare disease pipeline.
Net loss for the second quarter of 2025 was $2.5 million or $0.35 per share compared to net loss of $1.7 million or $0.49 per share for the second quarter of 2024.
Research and Development (“R&D”) Expenses
R&D expenses for the second quarter of 2025 were $1,730,000, compared to $1,130,978 for the second quarter of 2024. This represents an increase of $599,023 attributed to (1) a $636,300 increase in R&D personnel expenses including stock-based compensation, partially offset by (2) a net decrease of $37,277 in other R&D expenses.
General and Administrative (“G&A”) Expenses
G&A expenses for the second quarter of 2025 were $1,504,295, compared to $657,806 for the second quarter of 2024. This represents an increase of $846,489 primarily attributed to (1) a $370,103 increase in Board compensation resulting from the grant of stock options in March 2025 (no stock options were granted to the Board in 2024), (2) a $255,650 increase in G&A personnel expenses including stock-based compensation, (3) a $114,322 increase in legal fees, (4) a $63,200 increase in state franchise taxes, (5) a $41,416 increase in insurance expenses and (6) a net increase of $1,798 in other G&A expenses.
Interest Income
Interest income for the three months ended June 30, 2025, increased by $707,294 compared to the same period in 2024. The increase is attributed to interest earned on U.S. Treasury securities and higher bank balances in 2025, resulting from over $55 million of funds raised in the fourth quarter of 2024.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers. For more information, and links to SEC filings that contain detailed financial information, visit: https://ir.monopartx.com/quarterly-reports .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that Monopar is responsible for advancing the program commercially; that Monopar is preparing to submit an NDA to the FDA in early 2026; that Monopar continues its preclinical work with MNPR-101-Ac with the plan to enter the clinic in the future; and that Monopar expects that its current funds will be sufficient to continue operations at least through December 31, 2026. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com
Follow Monopar on social media for updates:
X: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ**
How does the transfer of the ALXN1840 IND application to Monopar Therapeutics Inc. MNPR impact the company's strategic direction and resource allocation for its clinical programs?
What are the anticipated milestones for Monopar Therapeutics Inc. MNPR in the lead-up to the NDA submission for ALXN1840 in early 2026?
Given the increased R&D and G&A expenses reported for Monopar Therapeutics Inc. MNPR, how does the company plan to manage its budget effectively while advancing its clinical trials?
What measures is Monopar Therapeutics Inc. MNPR taking to ensure its financial sustainability, especially in light of potential future funding needs for ongoing projects?
**MWN-AI FAQ is based on asking OpenAI questions about Monopar Therapeutics Inc. (NASDAQ: MNPR).
NASDAQ: MNPR
MNPR Trading
-2.29% G/L:
$57.28 Last:
92,984 Volume:
$57.76 Open:
